Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Zaman

Showing results (101-110 of 119) with videos related to

Pageof 12
Sort By:
Nature Communications|February 26, 2022
Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategiesValentina Cordo', Mariska T Meijer, Rico Hagelaar, et al.
Molecular Cancer Therapeutics|November 2, 2018
Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017Joost C M Uitdehaag, Jeffrey J Kooijman, Jeroen A D M de Roos, et al.
Oncotarget|April 19, 2017
Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell linesMarion A A Libouban, Jeroen A D M de Roos, Joost C M Uitdehaag, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 5, 2009
Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptorPetra de Kruijf, Jane van Heteren, Herman D Lim, et al.
Journal of Molecular Biology|May 26, 2017
Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative ActivityJoost C M Uitdehaag, Jos de Man, Nicole Willemsen-Seegers, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 5, 2005
Psychiatry in EuropeM Agius, R Zaman, S Singh, et al.
Molecular Cancer Therapeutics|September 3, 2016
Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 InhibitorsJoost C M Uitdehaag, Jeroen A D M de Roos, Martine B W Prinsen, et al.
British Journal of Pharmacology|November 23, 2012
Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexesA O Watts, M M H van Lipzig, W C Jaeger, et al.
Plos Medicine|December 21, 2016
IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing StudyYunlei Li, Jessica G C A M Buijs-Gladdines, Kirsten Canté-Barrett, et al.
Frontiers in Oncology|August 26, 2024
Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combinationElisa Zanini, Nicole Forster-Gross, Felix Bachmann, et al.
Pageof 12

Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
Nature Communications|February 26, 2022
Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategiesValentina Cordo', Mariska T Meijer, Rico Hagelaar, et al.
Molecular Cancer Therapeutics|November 2, 2018
Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017Joost C M Uitdehaag, Jeffrey J Kooijman, Jeroen A D M de Roos, et al.
Oncotarget|April 19, 2017
Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell linesMarion A A Libouban, Jeroen A D M de Roos, Joost C M Uitdehaag, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 5, 2009
Nonpeptidergic allosteric antagonists differentially bind to the CXCR2 chemokine receptorPetra de Kruijf, Jane van Heteren, Herman D Lim, et al.
Journal of Molecular Biology|May 26, 2017
Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative ActivityJoost C M Uitdehaag, Jos de Man, Nicole Willemsen-Seegers, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 5, 2005
Psychiatry in EuropeM Agius, R Zaman, S Singh, et al.
Molecular Cancer Therapeutics|September 3, 2016
Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 InhibitorsJoost C M Uitdehaag, Jeroen A D M de Roos, Martine B W Prinsen, et al.
British Journal of Pharmacology|November 23, 2012
Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexesA O Watts, M M H van Lipzig, W C Jaeger, et al.
Plos Medicine|December 21, 2016
IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing StudyYunlei Li, Jessica G C A M Buijs-Gladdines, Kirsten Canté-Barrett, et al.
Frontiers in Oncology|August 26, 2024
Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combinationElisa Zanini, Nicole Forster-Gross, Felix Bachmann, et al.
Pageof 12